Revolution Medicines (NASDAQ:RVMD – Get Free Report) had its price target boosted by equities research analysts at Needham & Company LLC from $236.00 to $240.00 in a research report issued on Thursday,Benzinga reports. Wedbush raised their price target on Revolution Medicines from $181.00 to $192.10 and gave the company an “outperform” rating in a research note on Thursday, July 23rd. Get Revolution Medicines alerts:Get Our Latest Stock Analysis on Revolution MedicinesRevolution Medicines Trading Up 2.0%RVMD opened at $197.30 on Thursday. Sell-side analysts expect that Revolution Medicines will post -7.92 earnings per share for the current fiscal year. Featured StoriesReceive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.